These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22817873)

  • 1. 177Lu-nimotuzumab.
    Wiwanitkit V
    Nucl Med Biol; 2012 Aug; 39(6):891. PubMed ID: 22817873
    [No Abstract]   [Full Text] [Related]  

  • 2. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
    Vera DR; Eigner S; Henke KE; Lebeda O; Melichar F; Beran M
    Nucl Med Biol; 2012 Jan; 39(1):3-13. PubMed ID: 21958849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
    Abbas N; Bruland ØS; Brevik EM; Dahle J
    Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor.
    Barta P; Laznickova A; Laznicek M; Vera DR; Beran M
    J Labelled Comp Radiopharm; 2013 May; 56(5):280-8. PubMed ID: 24285372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (131)I-Nimotuzumab - A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR.
    Kameswaran M; Samuel G; Dev Sarma H; Shinde SN; Dash A; Venkatesh M
    Appl Radiat Isot; 2015 Aug; 102():98-102. PubMed ID: 26002276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
    Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Vallabhajosula S; Kuji I; Hamacher KA; Konishi S; Kostakoglu L; Kothari PA; Milowski MI; Nanus DM; Bander NH; Goldsmith SJ
    J Nucl Med; 2005 Apr; 46(4):634-41. PubMed ID: 15809486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.
    Persson M; Gedda L; Lundqvist H; Tolmachev V; Nordgren H; Malmström PU; Carlsson J
    Cancer Res; 2007 Jan; 67(1):326-31. PubMed ID: 17210714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate.
    Schlom J; Siler K; Milenic DE; Eggensperger D; Colcher D; Miller LS; Houchens D; Cheng R; Kaplan D; Goeckeler W
    Cancer Res; 1991 Jun; 51(11):2889-96. PubMed ID: 1851665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
    Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.
    Repetto-Llamazares A; Abbas N; Bruland ØS; Dahle J; Larsen RH
    Anticancer Res; 2014 Jul; 34(7):3263-9. PubMed ID: 24982330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
    Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J
    Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
    Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
    Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.
    Knogler K; Grünberg J; Novak-Hofer I; Zimmermann K; Schubiger PA
    Nucl Med Biol; 2006 Oct; 33(7):883-9. PubMed ID: 17045168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts.
    Roberson PL; Yokoyama S; Rogers BE; Buchsbaum DJ
    Cancer Biother Radiopharm; 2003 Apr; 18(2):239-47. PubMed ID: 12804050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dosimetric model for the heterogeneous delivery of radioactive nanoparticles In vivo: a feasibility study.
    Satterlee AB; Attayek P; Midkiff B; Huang L
    Radiat Oncol; 2017 Mar; 12(1):54. PubMed ID: 28302144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.
    Reddy BK; Lokesh V; Vidyasagar MS; Shenoy K; Babu KG; Shenoy A; Naveen T; Joseph B; Bonanthaya R; Nanjundappa ; Bapsy PP; Loknatha ; Shetty J; Prasad K; Tanvir Pasha CR
    Oral Oncol; 2014 May; 50(5):498-505. PubMed ID: 24613543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
    Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
    J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.
    Persson M; Tolmachev V; Andersson K; Gedda L; Sandström M; Carlsson J
    Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1457-62. PubMed ID: 16193312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.